Parcival will develop a multi-analyte lab-on-a-chip platform for simultaneous detection of resistance patterns, biomarkers for severity of infection, and infectious pathogens from patients and air samples. It will enable point-of-care testing for immediate evidence-based therapy thereby reducing unspecific use of antibiotics.
Currently, most diagnostic tests are performed in large central laboratories. Samples are usually sent from small clinical institutes and doctor’s offices, processed at the central laboratory, and the results are then transmitted back. For many situations, this can render the diagnosis entirely impractical (emergency situations like acute, life-threatening infections or determining the virus load in transplanted organs) or generate a significant barrier due to long patient waiting times, which sometimes leads to omitting a detailed diagnosis overall for non-critical cases, such as mild cases of respiratory diseases. Examples of automated platforms for integrated nucleic acid diagnostics with the potential for point-of-care diagnostics are still rare.
The objective of PARCIVAL is to develop an integrated and automated multi-analyte lab-on-a-disk platform for the fast and reliable sample in answer out diagnosis of highly infectious respiratory pathogens, resistance patterns and biomarkers for individual severity of the infection. The platform format will be based on completely integrated microfluidic foil-disposables with no external connections except one rotational axis of the centrifugal processing device and the sample inlet ports. We are aiming at a multiplexing platform of up to 24 parameters simultaneously in a quantitative way.
The new diagnostic platform will detect the causative agent, resistance patterns, and severity of infection permitting a timely and especially specific, individual medication, reducing the unspecific use of antibiotics and leading to a targeted and thus more effective treatment.
Flexible multi-analyte Point of Care testing platforms, including multiplex DNA , RNA and biomarker testing will definitely find their way in doctors’s offices, small clinical institutes, hospitals as well as in large central laboratories.